Loading...
•
Jun 30, 2023
4DMT Q2 2023 Earnings Report
4D Molecular Therapeutics reported financial results for the second quarter of 2023 and provided operational highlights.
Key Takeaways
4DMT reported positive interim data from clinical trials for 4D-150 and 4D-710, completed target enrollment for the Phase 2 PRISM clinical trial, and entered a license agreement with Astellas Pharma, receiving $20 million upfront. They closed the quarter with $310 million in cash, cash equivalents, and marketable securities.
Presented positive interim data from the intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD).
Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July.
Presented positive interim data from the aerosolized 4D-710 Phase 1/2 AEROW clinical trial for patients with cystic fibrosis lung disease.
Entered license agreement with Astellas Pharma in July and received $20 million upfront with potential future milestones of up to $942.5 million.
Forward Guidance
4DMT anticipates multiple clinical data and regulatory interaction updates on lead clinical-stage product candidates 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease over the next 12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...